Literature DB >> 19867170

RELATION OF A beta(1)-GLYCOPROTEIN OF HUMAN SERUM TO THE COMPLEMENT SYSTEM.

H J Müller-Eberhard1, U Nilsson.   

Abstract

The protein of human serum, tentatively designated beta(1C)-globulin, was shown to possess serological activity and to be related to the complement system. Another serum protein (beta(1A)-globulin) was identified as the inactivated form of beta(1C)-globulin. Incubation of fresh serum with various immune precipitates or with soluble gamma-globulin aggregates at 37 degrees C. resulted in the removal of beta(1C)-globulin. Treatment of fresh serum with zymosan at 17 and 37 degrees C. had a similar effect. In both instances beta(1C)-globulin was removed from serum, apparently by conversion to beta(1A)-globulin. However, isolated beta(1C)-globulin did not react with immune precipitates or zymosan, nor did beta(1C)-globulin of serum previously heated at 56 degrees C. Highly purified beta(1C)-globulin was tested for complement component activity by means of the usual reagents. All of the preparations examined were found to reconstitute the hemolytic activity of guinea pig R(3). However, they failed to reconstitute R(3) obtained from human serum. Isolated beta(1A)-globulin was found to be inactive in all systems. When isolated beta(1C)-globulin in either phosphate or in borate buffer was stored at 37 degrees C., the activity detected by means of guinea pig R(3) declined within 6 days to 20 to 30 per cent of its original value. As the activity decreased, beta(1C)-globulin was gradually converted to beta(1A)-globulin. Addition of beta(1C)-globulin to a limited complement system (human C') caused an increase of both initial velocity and final degree of hemolysis. Although beta(1C)-globulin did not cause lysis of EAC'(1, 4, 2), it fully prevented the otherwise rapid decay of EAC'(1, 4, 2) at 37 degrees C., and so presumably interacted with this complex.

Entities:  

Year:  1960        PMID: 19867170      PMCID: PMC2137252          DOI: 10.1084/jem.111.2.217

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  14 in total

1.  The properdin system and immunity. VIII. Studies on the purification and properties of the third component of human complement.

Authors:  F R ARDAY; L PILLEMER; I H LEPOW
Journal:  J Immunol       Date:  1959-05       Impact factor: 5.422

2.  Separation of components of guinea pig complement by chromatography.

Authors:  H J RAPP; M R SIMS; T BORSOS
Journal:  Proc Soc Exp Biol Med       Date:  1959-04

3.  Studies on the mechanism of hemolysis by antibody and complement.

Authors:  M M MAYER
Journal:  Prog Allergy       Date:  1958

4.  Quantitative studies of the properdin-complement system. III. Kinetics of the reaction between C'3 and the properdin-zymosan complex.

Authors:  M A LEON
Journal:  J Immunol       Date:  1958-07       Impact factor: 5.422

5.  Complex nature of the step in immune hemolysis involving third component of complement.

Authors:  K AMIRAIAN; O J PLESCIA; G CAVALLO; M HEIDELBERGER
Journal:  Science       Date:  1958-01-31       Impact factor: 47.728

6.  Mechanism of immune hemolysis: recognition of two steps in the conversion of EAC' 1,4,2 to E.

Authors:  H J RAPP
Journal:  Science       Date:  1958-01-31       Impact factor: 47.728

7.  Observations on a pro-esterase associated with partially purified first component of human complement (C'1).

Authors:  I H LEPOW; O D RATNOFF; F S ROSEN; L PILLEMER
Journal:  Proc Soc Exp Biol Med       Date:  1956-05

8.  THE PREPARATION AND PHYSICOCHEMICAL CHARACTERIZATION OF THE SERUM PROTEIN COMPONENTS OF COMPLEMENT.

Authors:  L Pillemer; E E Ecker; J L Oncley; E J Cohn
Journal:  J Exp Med       Date:  1941-09-30       Impact factor: 14.307

9.  An alternative mechanism for the properdin system.

Authors:  R A NELSON
Journal:  J Exp Med       Date:  1958-10-01       Impact factor: 14.307

10.  Isolation and characterization of two beta1-glycoproteins of human serum.

Authors:  H J MULLER-EBERHARD; U NILSSON; T ARONSSON
Journal:  J Exp Med       Date:  1960-02-01       Impact factor: 14.307

View more
  17 in total

Review 1.  [ACTH AND CORTICOID TREATMENT OF NEUROLOGIC DISEASES].

Authors:  H BAMMER
Journal:  Dtsch Z Nervenheilkd       Date:  1963-07-10

2.  [On the quantitative determination of the complement by means of immune diffusion].

Authors:  S Marghescu
Journal:  Klin Wochenschr       Date:  1968-09-15

3.  High-voltage starch-gel electrophoresis in the study of post-albumin proteins and C'3(beta 1-c-globulin) polymorphism.

Authors:  E A Azen; O Smithies; O Hiller
Journal:  Biochem Genet       Date:  1969-06       Impact factor: 1.890

4.  The biology of complement. Introduction.

Authors:  P J Lachmann
Journal:  Springer Semin Immunopathol       Date:  1994

Review 5.  Human complementary component C'3: an appraisal.

Authors:  P K Seth; S Seth
Journal:  Hum Genet       Date:  1976-08-30       Impact factor: 4.132

Review 6.  The alternative pathway of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

7.  The antigenic and molecular alterations of C3 in the fluid phase during an immune reaction in normal human serum. Demonstration of a new conversion product, C3x.

Authors:  R E Spitzer; A E Stitzel; V L Pauling; N C Davis; C D West
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

8.  Localization of immunological complexes fixing beta1C (C3) in germinal centers of lymph nodes.

Authors:  K J Gajl-Peczalska; A J Fish; H J Meuwissen; D Frommel; R A Good
Journal:  J Exp Med       Date:  1969-12-01       Impact factor: 14.307

9.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

10.  The localization of in vivo bound complement in tissue section.

Authors:  P J LACHMANN; H J MULLER-EBERHARD; H G KUNKEL; F PARONETTO
Journal:  J Exp Med       Date:  1962-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.